Enanta initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson started Enanta Pharmaceuticals with an Outperform rating and $135 price target.
The company has "unique molecular optimization capabilities" that could translate into a "superior" product profile in a growing field of liver disease competitors, Olson tells investors in a research note.
He believes Phase 2 data in mid-2019 should drive upside while the company's early stage programs provide optionality.
News 
Market Data 
Discover 
AI
